Spyre Therapeutics Inc.
NASDAQ: SYRE · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Spyre Therapeutics Inc. (SYRE) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for SYRE.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
SYRE historical valuation range
Where current P/E sits in SYRE's own 5Y range.
SYRE intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
SYRE valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 650.22x
Is SYRE overvalued in 2026?
Spyre Therapeutics Inc. (SYRE) currently trades at $76.43 per share with a market capitalization of $7,015,905,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 23/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
SYRE currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 650.2x, the market is valuing the company primarily on its revenue rather than its earnings.
A standard DCF model does not produce reliable output for SYRE under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
Financial quality is a concern. The Piotroski F-Score of 3/9 flags weakening fundamentals that deserve closer scrutiny before the valuation case can be fully trusted.
Bottom line: SYRE appears richly valued on our framework, with a Smart Value Score of 23/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is SYRE overvalued?
SYRE scores 23/100 on our Smart Value Score (Grade F), a weak overall profile. A standard DCF is unreliable here given the profitability profile, so valuation leans on revenue-based measures like EV/Sales and the P/S percentile below.
What is SYRE's fair value?
A standard DCF is unreliable for SYRE given its current profitability profile. Revenue-based approaches like EV/Sales or the historical P/S percentile are more informative for this stock.
What P/E ratio does SYRE trade at?
SYRE does not have a meaningful P/E right now, usually a sign of unprofitability or an earnings transition. For unprofitable growth names, price-to-sales is the more useful gauge.
Is SYRE a buy based on valuation?
Our Smart Value rating for SYRE is Strong Sell, from a Smart Value Score of 23/100 that blends growth, quality, and valuation. The profile skews cautious, and a better price or clearer operating improvement would strengthen the case. This is research to inform your decision, not personalized financial advice.
How does SYRE's valuation compare to its history?
There is not enough historical valuation data yet for a confident percentile read on SYRE.
What is SYRE's Smart Value Score?
SYRE's Smart Value Score is 23/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.